Close Menu

NEW YORK — OpGen reported after the close of the market Wednesday a 17 percent increase in its third quarter revenues as it prepares for the planned merger with German diagnostics firm Curetis next year.

For the three-month period ended Sept. 30, OpGen posted revenues of $648,220 versus year-ago revenues of $552,221. Third quarter product sales rose 6 percent to $573,035 from $539,856, while the Gaithersburg, Maryland-based firm posted $75,000 in revenues from collaborations versus no such revenues in the same period last year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.